Pharmacokinetics and Pharmacodynamics Practice Questions

Q: A drug following first-order kinetics is administered by constant intravenous infusion at a rate of 10 mg/min. Its steady-state plasma concentration is 2 mg/L. If the dose rate is increased to 20 mg/min, what will be the new steady-state plasma concentration?

4 mg/L. ### Explanation **1. Why Option B is Correct:** The core concept here is **First-Order Kinetics**. In first-order kinetics, the rate of elimination is directly proportional to the plasma concentration [1]. For a drug administered by constant intravenous infusion, the steady-state concentration ($C_{ss}$) is determined by the formula: $\text{Dose Rate} = ext{Clearance (CL)} \times C_{ss}$ Rearranging this: $C_{ss} = \frac{\text{Dose Rate}}{\text{CL}}$ [2]. In first-order kinetics, **Clearance (CL) remains constant** regardless of the dose [1]. Therefore, $C_{ss}$ is directly proportional to the infusion rate. * Initial state: 10 mg/min results in 2 mg/L. * New state: The dose rate is doubled (20 mg/min). * Result: The $C_{ss}$ must also double. $2 \text{ mg/L} \times 2 = \mathbf{4 \text{ mg/L}}$. **2. Why Other Options are Incorrect:** * **Option A (6 mg/L):** This would imply a non-linear, disproportionate increase, which is not seen in first-order kinetics. * **Option C (3 mg/L):** This suggests a sub-proportional increase, which does not align with the linear relationship of first-order elimination. * **Option D (1 mg/L):** This would imply that increasing the dose decreases the concentration, which is physiologically impossible under these parameters. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Steady State:** It takes approximately **4 to 5 half-lives ($t_{1/2}$)** to reach steady state, regardless of the dose or infusion rate. * **Zero-Order Kinetics:** If a drug follows zero-order kinetics (e.g., Phenytoin, Ethanol, Aspirin at high doses), doubling the dose can lead to a massive, unpredictable increase in $C_{ss}$ because the elimination mechanisms are saturated [1]. * **Clearance:** In first-order kinetics, Clearance is constant; in zero-order kinetics, Clearance decreases as plasma concentration increases [1].

Q: Which drug has a wide therapeutic index?

Penicillin. ### Explanation **Therapeutic Index (TI)** is a quantitative measurement of a drug's safety. It is defined as the ratio of the dose that produces toxicity to the dose that produces a clinically desired effect ($TI = TD_{50} / ED_{50}$). **1. Why Penicillin is Correct:** Penicillin has a **wide therapeutic index**, meaning there is a large margin between the effective dose and the toxic dose. This is primarily because penicillin targets the bacterial cell wall (peptidoglycan synthesis), a structure that does not exist in human cells. Consequently, even very high doses are generally well-tolerated by the human body, unless the patient has a specific hypersensitivity/allergy. **2. Why the Other Options are Incorrect:** * **Digoxin (A):** A classic example of a **narrow therapeutic index** drug. It requires therapeutic drug monitoring (TDM) because the dose required to treat heart failure/arrhythmias is very close to the dose that causes life-threatening digitalis toxicity. * **Lithium (B):** Used in bipolar disorder, lithium has an extremely narrow window (therapeutic range: 0.6–1.2 mEq/L). Levels above 1.5 mEq/L can lead to severe neurotoxicity and renal impairment. * **Phenytoin (C):** This antiepileptic follows **zero-order kinetics** (saturation kinetics) at higher therapeutic concentrations. Small dose increases can lead to disproportionately large increases in plasma levels, causing toxicity (ataxia, nystagmus). **3. NEET-PG High-Yield Pearls:** * **Mnemonic for Narrow Therapeutic Index drugs:** "**W**arning, **T**hese **L**ethal **D**rugs **P**revent **C**uring" (**W**arfarin, **T**heophylline, **L**ithium, **D**igoxin, **P**henytoin/Phenobarbitone, **C**arbamazepine). * Drugs with a wide TI (e.g., Penicillin, Paracetamol, Benzodiazepines) are generally safer and do not require routine TDM. * **Low TI** = High risk of toxicity; **High TI** = Safer profile.

Q: Which of the following is not a prodrug?

Diazepam. **Explanation:** A **prodrug** is a pharmacologically inactive compound that must undergo metabolic conversion (usually in the liver) to become an active metabolite. **Diazepam** is the correct answer because it is an **active drug** itself. While it is metabolized into active metabolites like nordiazepam and oxazepam (contributing to its long duration of action), the parent compound possesses intrinsic therapeutic activity. **Analysis of Options:** * **Enalapril:** Most ACE inhibitors (except Captopril and Lisinopril) are prodrugs. Enalapril is converted by hepatic esterases into its active form, **Enalaprilat**. * **Sulindac:** This is a sulfoxide NSAID. It is inactive until metabolized into a **sulfide** derivative, which inhibits COX enzymes. This prodrug nature helps reduce direct gastric mucosal irritation. * **Cortisone:** This is a biologically inactive glucocorticoid. It must be converted into **Hydrocortisone (Cortisol)** by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) in the liver to be effective. **High-Yield NEET-PG Pearls:** 1. **Mnemonic for Prodrugs:** "**A**ll **P**harmacists **S**hould **C**an **D**eliver **E**very **M**edicine **I**n **L**iquid **S**tate" (**A**CEIs except Capto/Lisinopril, **P**roton Pump Inhibitors, **S**ulindac/Sulfasalazine, **C**yclophosphamide, **D**opa/Dipivefrine, **E**nalapril, **M**ercaptopurine, **I**rinotecan, **L**evodopa, **S**tatin/Spironolactone). 2. **Exceptions:** Captopril and Lisinopril are the only two ACE inhibitors that are **not** prodrugs. 3. **Clinical Significance:** Prodrugs may have poor efficacy in patients with severe liver disease due to impaired metabolic activation.

Q: What is the rate of drug elimination?

Clearance. **Explanation:** **1. Why Clearance is the Correct Answer:** **Clearance (CL)** is defined as the theoretical volume of plasma from which a drug is completely removed per unit of time (e.g., mL/min). It represents the **efficiency of drug elimination**. [1] Mathematically, it is expressed as: * **Rate of elimination = Clearance × Plasma Concentration (C)** [1] In first-order kinetics (followed by most drugs), clearance remains constant, meaning the rate of elimination is directly proportional to the plasma concentration. [2] **2. Analysis of Incorrect Options:** * **Half-life (T1/2):** This is the time required for the plasma concentration of a drug to reduce by 50%. While related to elimination, it is a measure of *time*, not the *rate* of volume cleared. * **Biotransformation:** This refers to the chemical alteration of a drug (metabolism), usually in the liver. While it is a *process* that contributes to elimination, it is not the definition of the rate itself. * **Bioavailability:** This is the fraction of an administered dose of unchanged drug that reaches the systematic circulation. It relates to *absorption*, not elimination. **3. High-Yield NEET-PG Clinical Pearls:** * **Zero-order Kinetics:** A few drugs (e.g., **P**henytoin, **A**lcohol, **W**arfarin, **S**alicylates—Mnemonic: **PAWS**) have a constant *rate* of elimination regardless of concentration because their metabolic enzymes are saturated. [2] * **Steady State:** It takes approximately **4 to 5 half-lives** to reach a steady-state concentration. * **Maintenance Dose Calculation:** Clearance is the most important pharmacokinetic parameter used to calculate the maintenance dose of a drug. * **Formula to remember:** $T_{1/2} = \frac{0.693 \times Vd}{CL}$. This shows that half-life is inversely proportional to clearance.

Q: High first-pass metabolism is characteristic of which of the following drugs?

All of the above. **Explanation:** **Concept of First-Pass Metabolism:** First-pass metabolism (presystemic elimination) refers to the extensive metabolism of a drug in the gut wall or liver before it reaches the systemic circulation. Drugs with high first-pass metabolism have low oral bioavailability, often necessitating higher oral doses or alternative routes of administration (e.g., sublingual, IV). **Analysis of Options:** * **Lignocaine (A):** It undergoes such extensive hepatic metabolism that its oral bioavailability is nearly zero. Therefore, it is never given orally for arrhythmias and is administered intravenously. * **Propranolol (B):** This is a classic example of a drug with high first-pass metabolism. The oral dose required to achieve therapeutic effects is significantly higher (e.g., 40–160 mg) compared to the intravenous dose (e.g., 1–3 mg). * **Salbutamol (C):** When taken orally, it undergoes significant metabolism in the gut wall by the enzyme sulfotransferase, leading to reduced bioavailability. Since all three drugs exhibit significant presystemic clearance, **Option D (All of the above)** is correct. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for High First-Pass Drugs:** "**L**ive **H**appily **P**rinting **M**oney **I**n **N**ew **T**exas" (**L**ignocaine, **H**ydrocortisone, **P**ropranolol/Pethidine, **M**orphine, **I**sosorbide dinitrate, **N**itroglycerin, **T**estosterone). * **Clinical Significance:** Patients with **liver cirrhosis** or portosystemic shunts may experience toxicity from these drugs due to decreased metabolism and increased systemic availability. * **Nitroglycerin:** Has the highest first-pass effect, which is why it is administered sublingually to bypass the liver.

Q: Which of the following statements regarding biotransformation is NOT true?

More lipid-soluble metabolites are formed.. **Explanation:** Biotransformation (metabolism) is the chemical alteration of a drug within the body. Its primary biological goal is to convert **lipid-soluble (lipophilic)** compounds into **water-soluble (hydrophilic)** metabolites. This change is essential because only water-soluble substances can be efficiently excreted by the kidneys; lipid-soluble substances are easily reabsorbed back into the bloodstream from the renal tubules. * **Why Option C is the correct answer (The "NOT true" statement):** Biotransformation almost never makes a drug more lipid-soluble. Increasing lipid solubility would hinder excretion and lead to drug accumulation and toxicity. * **Why Option A is wrong:** This is the most common outcome of metabolism (e.g., Phenytoin to inactive parahydroxy-phenytoin). It is often called "detoxification." * **Why Option B is wrong:** Some drugs are converted into active metabolites (e.g., Diazepam to Oxazepam) or are administered as inactive **prodrugs** that require metabolism to become active (e.g., Enalapril to Enalaprilat). * **Why Option D is wrong:** This is the fundamental purpose of Phase I and Phase II reactions—to increase polarity and water solubility for excretion. **High-Yield NEET-PG Pearls:** * **Phase I Reactions:** Include Oxidation (most common), Reduction, and Hydrolysis. These introduce or expose a functional group. * **Phase II Reactions:** Include Conjugation (e.g., Glucuronidation). These significantly increase water solubility. * **Exception to the Rule:** Most Phase II reactions inactivate drugs, but **Morphine-6-glucuronide** is a rare example of a Phase II metabolite that is more active than the parent drug. * **Microsomal Enzymes:** Located in the Smooth Endoplasmic Reticulum (e.g., CYP450); they are inducible and inhibitable.

Q: Intracellular receptors are found in which of the following substances?

Corticosteroids. **Explanation:** The location of a drug receptor is primarily determined by the **lipid solubility** of the ligand. **1. Why Corticosteroids are correct:** Corticosteroids (along with thyroid hormones, Vitamin D, and sex steroids) are highly **lipophilic**. This property allows them to easily cross the lipid bilayer of the cell membrane via simple diffusion. Once inside, they bind to **intracellular receptors** (specifically cytoplasmic receptors for steroids). The hormone-receptor complex then translocates to the nucleus, where it acts as a transcription factor, binding to the Hormone Response Element (HRE) on DNA to regulate gene expression. **2. Why other options are incorrect:** * **Insulin (Option A):** Insulin is a large peptide hormone. Being water-soluble and lipid-insoluble, it cannot cross the cell membrane. It binds to **Enzyme-linked receptors** (specifically Receptor Tyrosine Kinase) located on the cell surface. * **Glucagon (Option B):** Similar to insulin, glucagon is a peptide hormone. it acts via **G-Protein Coupled Receptors (GPCR)** on the cell surface, specifically using the adenylyl cyclase-cAMP second messenger system. **Clinical Pearls for NEET-PG:** * **Cytoplasmic Receptors:** Glucocorticoids, Mineralocorticoids, Progesterone, and Testosterone. * **Nuclear Receptors:** Thyroid hormones (T3/T4), Retinoic acid (Vitamin A), Vitamin D, and Estrogen. * **Speed of Action:** Receptors acting through gene transcription (Intracellular) have the **slowest onset of action** (hours to days) but the longest duration of effect compared to ion channels or GPCRs. * **Mnemonic:** "T-R-E-A-D" for Nuclear receptors: **T**hyroid, **R**etinoic acid, **E**strogen, **A**ldosterone (and other steroids), Vitamin **D**.

Q: Which class of drugs is highly bound to albumin?

Non-steroidal anti-inflammatory drugs (NSAIDs). **Explanation:** The binding of drugs to plasma proteins is a crucial pharmacokinetic parameter. The primary rule to remember for NEET-PG is that **acidic drugs bind to Albumin**, while **basic drugs bind to $\alpha_1$-acid glycoprotein (AAG)**. **1. Why NSAIDs are correct:** Non-steroidal anti-inflammatory drugs (NSAIDs), such as Ibuprofen, Naproxen, and Phenylbutazone, are **acidic drugs**. They have a high affinity for albumin (often >95% bound). Because they are highly protein-bound, they are susceptible to displacement interactions. For example, if two highly protein-bound acidic drugs are given together, one may displace the other, leading to a sudden increase in the free (active) fraction of the drug, potentially causing toxicity. **2. Why the other options are incorrect:** * **Lidocaine, Beta-blockers (e.g., Propranolol), and Verapamil** are all **basic drugs**. * Basic drugs primarily bind to **$\alpha_1$-acid glycoprotein (AAG)** and occasionally to lipoproteins. Therefore, they do not show significant binding to albumin compared to NSAIDs. **3. High-Yield Clinical Pearls for NEET-PG:** * **Albumin Binding (Acidic Drugs):** NSAIDs, Warfarin, Phenytoin, Penicillins, and Sulfonamides. * **$\alpha_1$-Acid Glycoprotein Binding (Basic Drugs):** Lidocaine, Quinidine, Bupivacaine, Propranolol, and Tricyclic Antidepressants (TCAs). * **Clinical Significance:** Only the **unbound (free) fraction** of a drug is pharmacologically active, metabolized, and excreted. * **Hypoalbuminemia:** In conditions like nephrotic syndrome or liver cirrhosis, the free fraction of acidic drugs (like Phenytoin) increases, necessitating dose adjustments to avoid toxicity.

Question 1

A drug following first-order kinetics is administered by constant intravenous infusion at a rate of 10 mg/min. Its steady-state plasma concentration is 2 mg/L. If the dose rate is increased to 20 mg/min, what will be the new steady-state plasma concentration?

Accepted Answer

4 mg/L

Answer

6 mg/L

Answer

3 mg/L

Answer

1 mg/L

Question 2

Which of the following factors is affected by the bioavailability of a drug?

Accepted Answer

Dose of the drug

Answer

Half-life of the drug

Answer

Volume of distribution

Answer

pKa value

Question 3

Which drug has a wide therapeutic index?

Accepted Answer

Penicillin

Answer

Digoxin

Answer

Lithium

Answer

Phenytoin

Question 4

Which of the following is NOT a feature of drugs acting through receptors?

Accepted Answer

Dependence of action on lipophilicity

Answer

Structural specificity

Answer

High potency

Answer

Competitive antagonism

Question 5

Which of the following is not a prodrug?

Accepted Answer

Diazepam

Answer

Enalapril

Answer

Sulindac

Answer

Cortisone

Question 6

What is the rate of drug elimination?

Accepted Answer

Clearance

Answer

Half-life (T1/2)

Answer

Biotransformation

Answer

Bioavailability

Question 7

High first-pass metabolism is characteristic of which of the following drugs?

Accepted Answer

All of the above

Answer

Lignocaine

Answer

Propranolol

Answer

Salbutamol

Question 8

Which of the following statements regarding biotransformation is NOT true?

Accepted Answer

More lipid-soluble metabolites are formed.

Answer

Inactive metabolites are formed.

Answer

Active metabolites are formed.

Answer

More water-soluble metabolites are formed.

Question 9

Intracellular receptors are found in which of the following substances?

Accepted Answer

Corticosteroids

Answer

Insulin

Answer

Glucagon

Answer

All of the above

Question 10

Which class of drugs is highly bound to albumin?

Accepted Answer

Non-steroidal anti-inflammatory drugs (NSAIDs)

Answer

Lidocaine

Answer

Beta blockers

Answer

Verapamil

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?